|
Feb 27
|
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
|
|
Feb 18
|
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025
|
|
Sep 24
|
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
|
|
Sep 23
|
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
|
|
Sep 23
|
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
|
|
Aug 30
|
Ventyx Biosciences Announces Departure of Chief Financial Officer
|
|
Aug 30
|
Novo builds heart failure case for semaglutide; Ventyx CFO departs
|
|
Jul 29
|
Ventyx’s TYK2 drug suffers second setback
|
|
Jul 29
|
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease
|
|
May 13
|
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress
|
|
May 2
|
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 30
|
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
|
|
Mar 11
|
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
|
|
Mar 7
|
NodThera says inflammation drug has positive effect in Parkinson’s
|
|
Mar 7
|
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
|
|
Mar 6
|
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
|
|
Mar 4
|
Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024
|
|
Dec 23
|
Ventyx Biosciences Inc CEO Raju Mohan Sells 58,860 Shares
|
|
Sep 8
|
Insider Sell: CFO Martin Auster Sells 26,472 Shares of Ventyx Biosciences Inc
|